Hermes Vector

HealthTrending

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Eli Lilly has agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, adding a preclinical antibody program for rare blood disorders to its hematology portfolio.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · हिन्दी · 中文

Checked against 3 sourcesca.finance.yahoo.comfinance.biggo.comcitybiz.co
Illustration for: Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

In brief

  • Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion in cash.
  • The deal includes an upfront payment and milestone payments, with the initial amount undisclosed.
  • Calytrix's lead preclinical antibody targets mutant calreticulin in essential thrombocythemia and myelofibrosis.
  • Calytrix was founded in 2025 by JP Morgan Life Sciences Private Capital.

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion

Eli Lilly and Company has entered into a definitive agreement to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, expanding its efforts to develop treatments for rare blood disorders and strengthen its presence in haematology.

Deal terms

Under the definitive agreement, Calytrix shareholders will receive an upfront payment followed by additional payments linked to clinical and regulatory milestones. The companies have not disclosed the initial payment or an expected completion date.

The asset

The acquisition centres on Calytrix's lead experimental programme, a preclinical antibody designed to treat essential thrombocythemia and myelofibrosis driven by mutations in the calreticulin protein. Both conditions belong to a group of diseases known as myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of abnormal blood cells.

The antibody is designed to target both Type 1 and Type 2 mutant calreticulin, with the aim of eliminating the disease-driving cells while preserving healthy tissue and blood-cell production.

Calytrix said existing drug treatments for the two conditions primarily manage symptoms and complications, creating an opportunity for therapies that target the underlying mutations and potentially alter the course of the diseases. However, the programme remains at the preclinical stage and must undergo clinical development before its safety and effectiveness in patients can be established.

Company background

Brad Prosek, Calytrix's chief executive, said the company was founded to develop treatments that could do more than manage symptoms and welcomed Lilly's plans to advance the programme through clinical trials.

The acquisition broadens Lilly's presence in the myeloproliferative neoplasm field and builds on its existing blood cancer portfolio, which includes the approved treatment Jaypirca.

Calytrix was founded in 2025 by JP Morgan Life Sciences Private Capital and subsequently received backing from Westlake BioPartners and Avoro Ventures.

Why it matters

The deal adds an early-stage rare blood disorder asset to Lilly's pipeline as the company continues deploying cash from its GLP-1 franchise into therapeutic areas beyond weight-loss drugs. The price tag is modest relative to Lilly's recent dealmaking pace and is unlikely to alter near-term earnings.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

Who is acquiring Calytrix Bio and for how much?
Eli Lilly and Company is acquiring the privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash.
What is the experimental asset involved in the deal?
The acquisition centers on a preclinical antibody designed to treat essential thrombocythemia and myelofibrosis driven by mutations in the calreticulin protein.
When was Calytrix founded and who backed it?
Calytrix was founded in 2025 by JP Morgan Life Sciences Private Capital and subsequently received backing from Westlake BioPartners and Avoro Ventures.
Why does this acquisition matter for Eli Lilly?
The deal adds an early-stage rare blood disorder asset to Lilly's pipeline as the company continues deploying cash from its GLP-1 franchise into therapeutic areas beyond weight-loss drugs.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

Boots to prescribe medical cannabis via video consultations

Boots is launching SureLeaf, an online medical cannabis service for UK patients aged 25 and over with eligible conditions, following online assessment and video consultation.

Checked against 6 sourcesThe Guardianglobalcosmeticsnews.combusinessofcannabis.com+3 more